GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC.

https://www.gehealthcare.com/

518-300-0738

brittany.tambasco@gehealthcare.com

BRITTANY TAMBASCO

P2954604

GE HEALTHCARE TECHNOLOGY & INNOVATION CENTER

75H70925P00091

View Award on USAspending website

AWARD

PURCHASE ORDER

Department of Health and Human Services

2025-05-01

15000.00

15000.00

15000.00

BFSU_GE CARESCAPE CENTRAL STATION PATIENT MONITORING V2 SYSTEM REPAIR

811210: ELECTRONIC AND PRECISION EQUIPMENT REPAIR AND MAINTENANCE

J065: MAINT/REPAIR/REBUILD OF EQUIPMENT- MEDICAL, DENTAL, AND VETERINARY EQUIPMENT AND SUPPLIES

HT942524C0108

View Award on USAspending website

AWARD

DEFINITIVE CONTRACT

Department of Defense

2024-09-30

2876898.00

2876898.00

2876898.00

MAGNETIC RESONANCE IMAGING (MRI) UPGRADE

334510: ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS MANUFACTURING

6525: IMAGING EQUIPMENT AND SUPPLIES: MEDICAL, DENTAL, VETERINARY

75N93024C00051

View Award on USAspending website

AWARD

DEFINITIVE CONTRACT

Department of Health and Human Services

2024-09-18

4211973.00

4211973.00

9673642.00

BAA2023-1 RESEARCH AREA 004: DEVELOPMENT OF IN VITRO DIAGNOSTICS FOR BIODEFENSE, ANTIMICROBIAL RESISTANT INFECTIONS (AMR), AND EMERGING INFECTIOUS DISEASES

541715: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)

AN12: HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

2025-03-17

View on USAspending

Department of Health and Human Services

A NOVEL MULTI-ANALYTE APPROACH TO DEMOCRATIZE CANCER BIOBANKING - PROJECT SUMMARY/ABSTRACT THE OBJECTIVE OF THIS PROPOSAL IS TO ESTABLISH A SIMPLIFIED AND ACCESSIBLE PROCEDURE FOR MULTI-ANALYTE SIMULTANEOUS EXTRACTION OF DNA, RNA, AND PROTEIN FROM TUMOR TOUCH IMPRINTS THAT DEMOCRATIZES BIOBANKING FOR LOW-RESOURCE INSTITUTES. TRADITIONAL BIOBANKING OF FRESH-FROZEN OR FFPE TISSUE IS RESOURCE-HEAVY AND REQUIRES DEDICATED STAFF, EXPERTISE, AND STORAGE FACILITIES THAT MAY NOT BE AVAILABLE AT SMALLER INSTITUTES, WHICH HAS THE UNINTENDED IMPACT OF DISENFRANCHISING LOWER SOCIOECONOMIC POPULATIONS. FOR EXAMPLE, ONLY 1 IN 10 SPECIMENS COLLECTED BY THE CAN- CER DISPARITIES RESEARCH NETWORK WERE FROM NON-WHITE PATIENTS. THUS, THERE IS A NEED FOR IMPROVEMENTS IN PRO- CUREMENT TECHNOLOGIES TO ADDRESS BIOBANKING DISCREPANCIES. IN ADDITION, EARLY DETECTION AND EARLY TREATMENT RE- SULTS IN INCREASINGLY SMALLER TUMOR SIZES OBTAINED AT SURGERY, WHICH REQUIRES MAXIMIZING MOLECULAR RECOVERY FROM A SINGLE SMALL SAMPLE. OUR PROPOSED APPROACH WILL LEVERAGE TUMOR TOUCH IMPRINTS ON GLASS SLIDES AS A METHOD FOR BIOBANKING, IN COMBINATION WITH A MULTI-ANALYTE MOLECULAR EXTRACTION PROTOCOL PREVIOUSLY DEVELOPED FOR FORENSIC APPLICATIONS. THE TECHNIQUE ENABLES SIMULTANEOUS RECOVERY OF DNA, RNA, AND PROTEIN FROM THE SAME SMALL SAMPLE, INCLUDING SAMPLES CONSISTING OF LESS THAN 10,000 CELLS. OUR AIMS INCLUDE OPTIMIZATION OF THE MO- LECULAR EXTRACTION PROTOCOL FROM AIR DRIED TOUCH IMPRINTS, AND DEMONSTRATION OF NON-INFERIORITY RELATIVE TO FRESH- FROZEN TISSUE AND CONVENTIONAL MOLECULAR EXTRACTION METHODS. WE WILL FURTHER OPTIMIZE PROCEDURES TO MINIMIZE PRE-ANALYTICAL VARIABLES AROUND STORAGE TIME, STORAGE METHOD, AND COMPATIBILITY WITH FIXATION AND CELLULAR STAIN- ING. MOLECULAR YIELD AND INTEGRITY WILL BE MEASURED AND COMPARED TO FRESH-FROZEN TISSUE. RECOVERED MOLECULAR CONTENT WILL BE ASSESSED BY DNA SEQUENCING, RNA SEQUENCING AND PROTEIN ANALYTICS (MASS SPECTROMETRY AND/OR PROTEIN ARRAYS). IF SUCCESSFUL, OUR APPROACH COULD PROVIDE A SIMPLIFIED METHOD FOR MULTI-PARAMETRIC ANALYSIS OF SMALLER SIZED TUMORS, INCLUDING GENOMIC ANALYSIS, GENE EXPRESSION PROFILING, AND PROTEIN EXPRESSION AND ACTIVA- TION, BROADENING THE OPTIONS FOR BIOMARKER DISCOVERY AS WELL AS ENABLING CORRELATIVE ANALYSIS OF ALL ANALYTES FROM THE SAME SAMPLE.

440287.00

0.00

0.00

2024-09-13

View on USAspending

Department of Health and Human Services

POINT OF CARE DETECTION AND DIAGNOSIS OF ORAL CANCER USING A LOW COST IMAGING MODULE ENABLED BY AI - PROJECT SUMMARY/ABSTRACT THE OVERALL VISION OF THE PROPOSED PROJECT IS TO TO DEVELOP AND DEPLOY AN AFFORDABLE AUTOMATED POINT-OF-CARE (POC) TELECYTOLOGY PLATFORM FOR ORAL CANCER SCREENING THAT WILL RELIABLY ESTABLISH A DIAGNOSIS OF ORAL CANCER IN THE COMMUNITY SETTING AND ESTABLISH AN IMMEDIATE REFERRAL CARE PATHWAY. ORAL CANCER IS A SIGNIFICANT PUBLIC HEALTH PROBLEM IN INDIA; 77,000 NEW CASES AND 52,000 DEATHS ARE REPORTED ANNUALLY, WHICH IS APPROXIMATELY ONE-FOURTH OF GLOBAL INCIDENCES. APPROXIMATELY 70% OF CASES PRESENT AT AN ADVANCED STAGE, WHEN THE PROBABILITY OF CURE IS VERY LOW, AND A FIVE-YEAR SURVIVAL RATE IS AROUND 20%. IT HAS BEEN ESTIMATED THAT EARLY DIAGNOSIS, WITH TIMELY AND PROPER TREATMENT, COULD IMPROVE THE SURVIVAL RATE UP TO 90%. THE CURRENT ‘GOLD STANDARD’ OF ORAL CANCER SCREENING IS VISUAL INSPECTION OF THE MOUTH BY TRAINED INDIVIDUALS, FOLLOWED BY BIOPSY OF SUSPICIOUS LESIONS. HOWEVER, IN INDIA THERE IS A DELAY OF NINE MONTHS FROM THE ONSET OF SYMPTOMS TO DIAGNOSIS. OF THIS, SEVEN MONTHS ARE ATTRIBUTED TO THE DELAYS WITHIN THE MEDICAL PATHWAY THE MAJORITY OF THE POPULATION LIVES IN A RURAL ENVIRONMENT, WHERE ACCESS TO PATHOLOGY SERVICES AND EXPERTISE IS VERY LIMITED. WITHOUT DEFINITIVE PROOF OF CANCER, PATIENTS ARE NOT ELIGIBLE FOR STATE-RUN INSURANCE PROGRAMS FOR TREATMENT. OUR PROPOSED APPROACH COMPRISES A PORTABLE SYSTEM FOR SCANNING BRUSH BIOPSY CYTOLOGY SLIDES WITH CLOUD CONNECTIVITY FOR TRANSMISSION OF IMAGES TO PATHOLOGISTS AND/OR AUTOMATED DIAGNOSIS VIA A VALIDATED ALGORITHM FOR IDENTIFICATION OF ATYPICAL CELLS. AFTER STANDARD VISUAL TRIAGING OF PATIENTS DURING ROUTINE SCREENING, THOSE IDENTIFIED WITH HIGHER RISK LESIONS WILL IMMEDIATELY BE DIRECTED TO UNDERGO BRUSH BIOPSIES ON THE SAME DAY. SAMPLES WILL BE PLACED ON A GLASS SLIDE, STAINED WITH ROUTINE TOLUIDINE BLUE (AVERAGE TIME IS <4 MINUTES), AND IMAGED USING THE PORTABLE SLIDE SCANNER. INITIALLY THESE IMAGES WILL BE RELAYED VIA CLOUD TO A REMOTE PATHOLOGIST WHO WILL IMMEDIATELY REPORT THEM, WHILE SUBSEQUENT VERSIONS OF THE PROTOTYPE WILL HAVE IN-BUILT ARTIFICIAL INTELLIGENCE (AI) ALGORITHMS FOR AUTOMATED REPORTING IN THE FIELD. WE BELIEVE THAT THIS INNOVATIVE AND AFFORDABLE WORKFLOW WOULD SUCCESSFULLY EXPEDITE DIAGNOSIS AND PROVIDE SIGNIFICANTLY EARLIER TREATMENT FOR ORAL CANCER PATIENTS.

478576.00

0.00

0.00

2024-03-08

View on USAspending

Department of Health and Human Services

LIGHTWEIGHT, COMPACT, LOW-CRYOGEN, HEAD-ONLY 7T MRI FOR HIGH SPATIAL RESOLUTION BRAIN IMAGING - PROJECT SUMMARY/ABSTRACT AN INNOVATIVE HEAD-ONLY 7T MRI SYSTEM THAT DELIVERS SPATIAL RESOLUTION THAT IS DIFFICULT TO ACHIEVE WITH TODAY'S WHOLE-BODY 7T SYSTEMS, AND HAS THE FOOTPRINT AND WEIGHT OF A WHOLE-BODY 3T SCANNER IS PROPOSED. THIS NEW IM- AGING SYSTEM COMBINES A HIGH-PERFORMANCE ASYMMETRICAL HEAD GRADIENT THAT DELIVERS 130 MT/M AND 900 T/M/S PERFORMANCE IN AN ACTIVELY SHIELDED, LOW-CRYOGEN, LIGHTWEIGHT HEAD-ONLY 7T MAGNET. THE MULTI-DISCIPLINARY GROUP FROM GE GLOBAL RESEARCH, THE UNIVERSITY OF CALIFORNIA-SAN FRANCISCO, AND THE MAYO CLINIC WILL DELIVER THIS UNIQUE IMAGING TOOL TO BETTER UNDERSTAND AND DISCOVER NEW BRAIN PROCESSES. THE HIGH GRADIENT AMPLITUDE AND HIGH SLEW RATE WILL BE LEVERAGED TO DEVELOP APPLICATIONS FOR HIGH SPATIAL RESOLUTION IMAGING OF BRAIN MICROSTRUC- TURE, FUNCTIONAL BRAIN ACTIVATION, ARTERIAL AND VENOUS VASCULATURE, AND TO PROFILE BRAIN METABOLITES THAT ARE CRITI- CAL TO NEUROTRANSMISSION AND BRAIN FUNCTION, ESPECIALLY IN REGIONS OF THE BRAIN THAT HAVE PREVIOUSLY ELUDED RE- SEARCHERS DUE TO RESOLUTION AND SUSCEPTIBILITY LIMITATIONS. THE PROPOSED HEAD-ONLY 7T MR SYSTEM IS DRAMATICALLY SMALLER AND 70% LIGHTER WEIGHT COMPARED TO OTHER ULTRA-HIGH FIELD MRI SYSTEMS. THIS ENABLES A HIGH-RESOLUTION BRAIN RESEARCH PLATFORM TO BE INSTALLED IN LOCATIONS THAT OTHERWISE COULD NOT SUPPORT A CONVENTIONAL ULTRA-HIGH FIELD MRI SYSTEM, PROVIDING GREATER ACCESS TO THIS TECHNOLOGY TO INCREASE KNOWLEDGE GENERATION OF HOW THE BRAIN WORKS.

13925807.16

0.00

0.00

2024-03-13

View on USAspending

Department of Health and Human Services

FUNCTIONAL MAGNETIC RESONANCE IMAGING AND DEEP LEARNING TO IMPROVE DEEP BRAIN STIMULATION THERAPY - PROJECT SUMMARY/ABSTRACT SUCCESSFUL TREATMENT OF PARKINSON'S DISEASE (PD) USING DEEP BRAIN STIMULATION (DBS) THERAPY REQUIRES AN OPTIMAL SETTING OF STIMULATION PARAMETERS TO CORRECT BRAIN FUNCTION ANOMALIES. THE COMMONLY EMPLOYED DBS 1.0 ELECTRODES HAVE ONLY FOUR CONTACT LOCATIONS (WITH NO STIMULATION DIRECTIONALITY) THAT ARE USED TO ELECTRIC PULSES TO A TARGET VOLUME OF THE BRAIN. DBS 1.0 ELECTRODES REQUIRE THE OPTIMIZATION OF FOUR STIMULATION PARAMETERS: SIGNAL FREQUENCY, VOLTAGE, PULSE WIDTH, AND CONTACT LOCATION. IN CURRENT STANDARD-OF-CARE OPTIMIZATION PROTOCOL, THE DBS PARAMETERS ARE ADJUSTED (VIA TRIAL AND ERROR) UNTIL THE PHYSICIAN DETERMINES AN OPTIMAL SET OF PARAMETERS. THIS EMPIRICAL OPTIMIZATION PROTOCOL REQUIRES NUMEROUS CLINICAL VISITS (~6 WEEKS INTERVAL) THAT SUBSTANTIALLY INCREASES THE TIME TO OPTIMIZATION (TTO) PER PATIENT (~1 YEAR), FINANCIAL BURDEN, AND ULTIMATELY LIMITS THE NUMBER OF PATIENTS THAT CAN HAVE ACCESS TO DBS THERAPY. EVEN THOUGH THERE ARE MORE EFFECTIVE ELECTRODES, DBS 1.0 ELECTRODES ARE MOSTLY USED BY CLINICIANS BECAUSE THEIR SMALLER PARAMETER SPACE POSE LESS DIFFICULTY DURING MANUAL CLINICAL OPTIMIZATION. HOWEVER, DBS 1.0 ELECTRODES CANNOT BE DIRECTED TO STIMULATE A SMALLER VOLUME OF TISSUE, WHICH CAN LEAD TO EXTRANEOUS STIMULATIONS THAT CAN REDUCE PATIENT CLINICAL BENEFITS AND INCREASE SIDE EFFECTS. BY CONTRAST, THE NEWER DBS ELECTRODES (DUBBED DBS 2.0) HAVE A GREATER NUMBER OF CONTACT LOCATIONS AND CAN BE PROGRAMMED TO STIMULATE A SMALLER VOLUME OF TISSUE AT MULTIPLE LEVELS AND DIRECTIONS. SEVERAL PUBLISHED REPORTS HAVE SHOWN THAT DBS 2.0 ELECTRODES (COMPARED TO DBS 1.0) ARE MORE ENERGY-EFFICIENT AND IMPROVE PATIENT OUTCOMES WITH LESSER SIDE-EFFECTS AND A WIDER THERAPEUTIC WINDOW. HOWEVER, THE EXPANDED DBS 2.0 PARAMETER SPACE HAS MADE EMPIRICAL PROGRAMMING OF THE ELECTRODES DIFFICULT AS THE TTO PER PATIENT IS BEYOND ACCEPTABLE CLINICAL TIMEFRAMES. THIS INCREASED DIFFICULTY HAS HINDERED ADOPTION OF DBS 2.0 ELECTRODES BY CLINICIANS. TO SIGNIFICANTLY SHORTEN AND SIMPLIFY DBS 2.0 PARAMETER OPTIMIZATION—THUS ENABLING ITS WIDER ADOPTION FOR MORE PRECISE THERAPY—A UNIQUELY QUALIFIED MULTI- DISCIPLINARY TEAM OF MAGNETIC RESONANCE IMAGING (MRI) PHYSICISTS, ARTIFICIAL INTELLIGENCE (AI) ENGINEERS, AND CLINICIANS FROM GE RESEARCH AND THE UNIVERSITY HEALTH NETWORK PROPOSE TO: 1) DEVELOP A SEMI-AUTOMATED FUNCTIONAL MRI (FMRI) AND DEEP LEARNING (DL)-BASED SYSTEM FOR RAPID OPTIMIZATION OF DBS 2.0 PARAMETERS; 2) DEMONSTRATE ITS CLINICAL BENEFIT IN THE TREATMENT OF PD PATIENTS USING BILATERAL STIMULATION OF THE SUB-THALAMIC NUCLEUS WITH DBS 2.0 ELECTRODES IN A PILOT STUDY. SUCCESS OF THIS PROGRAM WILL DECREASE THE TTO PER PATIENT FOR PD PATIENTS WITH DBS 2.0 IMPLANTS TO ~1 HOUR, AND WILL IMPROVE PATIENT THROUGHPUT AND OUTCOMES IN THE TREATMENT OF PD. THE PROPOSED FMRI-DL-BASED OPTIMIZATION METHOD MAY ALSO IMPROVE ACCESS BY MAKING IT POSSIBLE FOR NON-EXPERT CENTERS (WITHOUT HIGHLY SPECIALIZED CLINICIANS) TO CARRY OUT STIMULATION PARAMETERS OPTIMIZATION IN PATIENTS AFTER THE ELECTRODE INSERTION SURGERY HAVE BEEN COMPLETED IN EXPERT CENTERS.

1135170.00

0.00

0.00

2024-07-26

View on USAspending

Department of Health and Human Services

ENABLING CLINICAL TISSUE MICROSTRUCTURE IMAGING AS A DIAGNOSTIC TOOL IN WIDE-BORE 3T MRI - PROJECT SUMMARY/ABSTRACT DEFINITIVE CHARACTERIZATION OF CYTOARCHITECTURE AND ITS ALTERNATION IS KEY TO CLINICAL DIAGNOSIS AND PATIENT MANAGEMENT IN DISEASE, INCLUDING CANCER. CURRENT STANDARD-OF-CARE OF SUCH MICROSTRUCTURE CHARACTERIZATION IS BASED PRIMARILY ON HISTOPATHOLOGICAL ASSESSMENT VIA BIOPSY SAMPLING OF SUSPECTED LESIONS. HOWEVER, INVASIVE BIOPSY PROCEDURES CARRY BURDENS OF PROCEDURE COMPLEXITY, SAMPLING ERRORS, AND COMPLICATIONS. THUS, IT IS DESIRABLE TO HAVE A NON-INVASIVE, HIGH-SENSITIVITY, HIGH-SPECIFICITY IMAGING TOOL THAT ACCURATELY ASSESSES TUMOR MICROSTRUCTURES THAT ARE COMPARABLE TO THAT OBTAINED FROM BIOPSY/HISTOPATHOLOGY. THIS WILL HAVE THE CLINICALLY SIGNIFICANT RESULT OF REDUCING UNNECESSARY BIOPSIES AT THE MINIMUM, AND PERHAPS REDUCE THE OVERALL NUMBER OF BIOPSY PROCEDURES AND REPEAT BIOPSIES. FURTHERMORE, THIS WILL SIGNIFICANTLY IMPROVE THE PRECISION OF BIOPSY TO SAMPLE CLINICALLY SIGNIFICANT CANCERS AND REGIONS MOST RELEVANT TO CANCER PROGNOSIS. WE PROPOSE TO APPLY ADVANCED DIFFUSION MRI (DMRI), INCLUDING NOVEL OSCILLATING GRADIENT SPIN ECHO (OGSE) DIFFUSION ENCODING, FOR TUMOR MICROSTRUCTURE IMAGING AND THE PILOT APPLICATION WILL BE TO IMPROVE CHARACTERIZATION OF THE EPITHELIUM, STROMA, AND LUMEN VOLUME FRACTIONS WHICH ARE HIGHLY CORRELATED TO PROSTATE CANCER GRADES. OGSE DMRI HAS BEEN ATTEMPTED IN CLINICAL WHOLE-BODY MRI BUT THE TECHNIQUE HAS HAD ONLY MODEST SUCCESS DUE TO THE LIMITED GRADIENT PERFORMANCE OF WHOLE-BODY MRI SCANNERS. THE GRADIENT AMPLITUDE AND SLEW RATE OF EXISTING CLINICAL WHOLE-BODY 3.0T MRI SCANNERS ARE OFTEN CONSTRAINED BY PEAK POWER OF THE GRADIENT DRIVER. MANY CLINICAL 70- CM WIDE-BORE MRI SYSTEMS OPERATE AT 1 MVA PEAK POWER, WHILE SOME HIGH-END SYSTEMS INCREASE THE PEAK POWER TO 2-2.7 MVA. HOWEVER, THE 2-3X HIGHER PEAK POWER SUBSTANTIALLY INCREASES THE OVERALL COST OF MRI SYSTEMS AND REQUIRES MAJOR INCREASES TO THE HOSPITAL'S ELECTRICAL SERVICE AND COOLING INFRASTRUCTURE TO ACCOMMODATE INCREASED ELECTRICAL POWER AND THERMAL LOADS. CONSEQUENTLY, SUCH UPGRADES BECOME COST PROHIBITIVE AND ARE IMPRACTICAL FOR WIDE ADOPTION. OUR TECHNICAL SOLUTION IS TO BUILD A NEW 4 MVA SILICON CARBIDE (SIC) SEMICONDUCTOR GRADIENT DRIVER WHICH REPLACES A CONVENTIONAL SILICON 1 MVA OR 2 MVA GRADIENT DRIVER IN CLINICAL 3.0T WIDE-BORE MRI SCANNERS WITHOUT REQUIRING ANY CHANGES TO FACILITY INFRASTRUCTURE. WE HAVE ASSEMBLED A DIVERSE, MULTI-DISCIPLINARY TEAM FROM GE RESEARCH, MEMORIAL SLOAN KETTERING CANCER CENTER, AND STANFORD UNIVERSITY TO DEVELOP MRI TOOLS AND METHODS TO ADDRESS CLINICAL NEEDS OF NON-INVASIVE TUMOR MICROSTRUCTURE IMAGING TO SOLVE CLINICALLY SIGNIFICANT PROBLEMS IN CANCER. WE WILL DEMONSTRATE TUMOR MICROSTRUCTURE IMAGING ENABLED BY HIGHER GRADIENT AMPLITUDE AND SLEW RATE CAN PROVIDE CLINICAL DIAGNOSTIC INFORMATION ON TUMOR CHARACTERIZATION COMPARABLE TO THAT OBTAINED FROM BIOPSY AND MOVE CLOSER TO THE GOAL OF REDUCING UNNECESSARY BIOPSIES. WE WILL DEMONSTRATE THE CLINICAL SIGNIFICANCE IN PROSTATE CANCER, AS IT IS THE SECOND LEADING CAUSE OF DEATH IN MEN. IT IS APPLICABLE TO OTHER CANCERS AND A BROAD RANGE OF CLINICAL APPLICATIONS WHERE NON-INVASIVE TUMOR MICROSTRUCTURE CHARACTERIZATION WILL SIGNIFICANTLY IMPROVE PATIENT MANAGEMENT.

2081856.00

0.00

0.00